Ultragenyx (NASDAQ:RARE) downgraded to Neutral with a $72 (20% upside) price target by H.C.Wainwright. SunTrust reiterates Buy rating and increased price target to $105 (75% upside) from $100. Shares are up 10% premarket on light volume on positive late-stage data on burosumab.
UnitedHealth Group (NYSE:UNH) reiterated Outperform with $187 (9% upside) price target by Oppenheimer.
Now read: ContraFect: More Dilution In Store »